C. Fagard

发表

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

A. Telenti, T. Perneger, H. Günthard, 2003, Archives of internal medicine.

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

H. Günthard, R. Weber, C. Fagard, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

C. Fagard, Y. Yazdanpanah, B. Spire, 2018, The Journal of antimicrobial chemotherapy.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recent developments in clinical trial designs for HIV vaccine research

C. Fagard, Y. Lévy, R. Thiébaut, 2015, Human vaccines & immunotherapeutics.

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

C. Fagard, C. Rouzioux, Y. Lévy, 2009, AIDS.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

C. Fagard, O. Lortholary, E. Caumes, 2016, The Journal of antimicrobial chemotherapy.

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2014, AIDS.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

C. Katlama, C. Fagard, B. Spire, 2018, The lancet. HIV.

Pharmacokinetics of etravirine , raltegravir and darunavir / ritonavir in treatment experienced patients

C. Katlama, C. Fagard, Y. Yazdanpanah, 2010 .

Tropism distribution among antiretroviral-naive HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, C. Fagard, 2015, AIDS.

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

C. Charpentier, P. Harrigan, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

C. Fagard, V. Veloso, J. Molina, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection

A. Telenti, C. Fagard, P. Vernazza, 2000, AIDS.

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.

C. Delaugerre, C. Fagard, V. Veloso, 2014, The Lancet. Infectious diseases.

Characterization of Binding of Raltegravir to Plasma Proteins

C. Fagard, Y. Yazdanpanah, J. Molina, 2013, Antimicrobial Agents and Chemotherapy.

Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load

H. Günthard, C. Fagard, A. Oxenius, 2002, AIDS (London).

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.

A. Trkola, H. Günthard, R. Weber, 2004, Blood.

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

T. Perneger, H. Günthard, C. Fagard, 2004, AIDS.

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

R. Salamon, F. Brun-Vézinet, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Drug Resistance Mutations during Structured Treatment Interruptions

H. Günthard, C. Fagard, S. Yerly, 2002, Antiviral therapy.

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2013, PloS one.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2010, AIDS.

Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).

C. Fagard, C. Rouzioux, G. Chêne, 2010, The Journal of antimicrobial chemotherapy.

A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART

A. Telenti, T. Perneger, H. Günthard, 2003, AIDS.

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

C. Charpentier, C. Fagard, Y. Yazdanpanah, 2012, Antimicrobial Agents and Chemotherapy.

Biphasic decline of CD4 cell count during scheduled treatment interruptions

T. Perneger, H. Günthard, C. Fagard, 2005, AIDS.

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.

C. Fagard, C. Rouzioux, F. Raffi, 2016, The Journal of antimicrobial chemotherapy.

Functional Discrepancies in HIV-Specific CD8+ T-Lymphocyte Populations Are Related to Plasma Virus Load

S. Rowland-Jones, H. Günthard, C. Fagard, 2002, Journal of Clinical Immunology.

Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3

G. M. Ortiz, D. Nixon, C. Fagard, 2004, Journal of acquired immune deficiency syndromes.

Reply to comment on 'pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'

C. Katlama, C. Fagard, Y. Yazdanpanah, 2011 .

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

C. Fagard, B. Masquelier, D. Breilh, 2009, The Journal of antimicrobial chemotherapy.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

C. Charpentier, C. Fagard, F. Raffi, 2013, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

A. d’Arminio Monforte, C. Fagard, F. Bai, 2010, AIDS.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.

C. Delaugerre, C. Fagard, V. Veloso, 2014, The Lancet. Infectious diseases.

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).

B. Autran, C. Fagard, C. Rouzioux, 2016, The Journal of antimicrobial chemotherapy.